Submit an order form online, via fax, or by email.

If you have questions, we are here to help. Call Foundation Medicine Client Services at 888.988.3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours. For even simpler ordering, log in or sign up for a Foundation Medicine account.

To order a FoundationOne®, FoundationOne®Heme, FoundationACT®, or FoundationFocus™CDxBRCA test for a patient:

  1. Download and complete the appropriate Test Requisition Form below. When applicable, include the contact information for the pathologist and institution where Foundation Medicine can retrieve the patient’s tumor specimen for analysis.
  2. Fax the requisition form, along with the pathology report and insurance information, to 617.418.2290.

To order a specimen kit for any of our tests, please contact a Client Services Representative at 888.988.3639 or client.services@foundationmedicine.com.

If sending a solid tumor specimen, Foundation Medicine will complete the rest of the specimen retrieval process. We will contact the pathologist and send a Specimen Collection Kit with instructions for sample procurement and shipment.

If sending peripheral blood or bone marrow aspirate, please follow the specimen preparation instructions for liquid specimens.


FoundationOne

Ordering Overview

Patients with solid tumors can be tested with FoundationOne with an FFPE tissue sample.

When submitting specimens to Foundation Medicine, please include the following items in the FoundationOne Specimen Kit:

Easy-to-understand test results are available online or via fax in less than 14 days. Reports match cancer patients’ molecular information with targeted therapies, immunotherapies, and clinical trials to expand treatment options.

Forms & Downloads

FoundationOneHeme

Ordering Overview

Patients with hematologic malignancies and sarcomas can be tested with FoundationOneHeme, which is performed on FFPE, peripheral whole blood or bone marrow aspirate specimens.

When submitting specimens to Foundation Medicine, please include the following items in the FoundationOneHeme Specimen Kit:

Note for Bone Samples: Do not use strong acids to decalcify. Hydrochloric acid should be avoided; EDTA is recommended, and formic acid has mixed results. Place sample in decalcifying solution for minimal amount of time. Using a weaker acid and shorter time for decalcifying preserves the nucleic acid and increases likelihood for getting results on bone samples.

Easy-to-understand test results are available online or via fax in approximately 14 days. Reports match cancer patients’ molecular information with targeted therapies, immunotherapies, and clinical trials to expand treatment options.

Forms & Downloads

FoundationACT

Ordering Overview

Patients with solid tumors can be tested using our liquid biopsy, FoundationACT, which requires two tubes of peripheral whole blood.

When submitting specimens to Foundation Medicine, please include the following items in the FoundationACT Specimen Kit:

Easy-to-understand test results are available online or via fax in less than 14 days. Reports match cancer patients’ molecular information with targeted therapies, immunotherapies, and clinical trials to expand treatment options.

Forms & Downloads

FoundationFocus CDxBRCA

Ordering Overview

Ovarian cancer patients can be tested with FoundationFocus CDxBRCA with an FFPE tissue sample, when you are considering treatment with Rubraca™ (rucaparib). FoundationFocus CDxBRCA is a companion diagnostic to Clovis Oncology's drug Rubraca, a poly (ADP-ribose) polymerase (PARP) inhibitor.

When submitting specimens to Foundation Medicine, please include the following items in the FoundationFocus CDxBRCA Specimen Kit:

Easy-to-understand test results are available online or via fax typically 2 weeks from receipt of specimen. Reports include BRCA1/2 alteration status (may be somatic or germline). Specimens that are found to have a deleterious BRCA alteration in their tumor tissue (tBRCA+) may be eligible for treatment with Rubraca (rucaparib) therapy.

Forms & Downloads